PPAR研究是一份同行評審的開放獲取期刊,發(fā)表有關(guān)基礎(chǔ)研究進展的原創(chuàng)研究和評論文章,重點關(guān)注過氧化物酶體增殖激活受體(PPAR)的激活機制,以及它們在細胞分化、發(fā)育、能量穩(wěn)態(tài)和代謝功能調(diào)控中的作用。該雜志還歡迎能夠調(diào)節(jié)PPAR活性的藥物的臨床前和臨床試驗,以期治療慢性疾病和疾病,如血脂異常、糖尿病、脂肪細胞分化、炎癥、癌癥、肺病、神經(jīng)退行性疾病和肥胖。PPAR的研究被歸檔在Portico,它為電子學術(shù)期刊提供了永久的歸檔,也通過LOCKSS計劃。它運行一個完全開放的訪問發(fā)布模型,允許對其發(fā)布的內(nèi)容進行開放的全局訪問。這個模型是通過文章處理費來支持的。有關(guān)一般文章處理費的更多信息,請點擊這里。PPAR研究包括在許多領(lǐng)先的抽象和索引數(shù)據(jù)庫中。點擊這里查看完整列表。PPAR研究由穆斯塔法·扎基·巴德教授于2005年創(chuàng)立,他曾在2005年至2011年間擔任該雜志的主編。根據(jù)Clarivate Analytics在2017年發(fā)布的2016年期刊引文報告,PPAR研究的最新影響因素是2.811。
PPAR Research is a peer-reviewed, Open Access journal that publishes original research and review articles on advances in basic research focusing on mechanisms involved in the activation of peroxisome proliferator-activated receptors (PPARs), as well as their role in the regulation of cellular differentiation, development, energy homeostasis and metabolic function. The journal also welcomes preclinical and clinical trials of drugs that can modulate PPAR activity, with a view to treating chronic diseases and disorders such as dyslipidemia, diabetes, adipocyte differentiation, inflammation, cancer, lung diseases, neurodegenerative disorders, and obesity.PPAR Research is archived in Portico, which provides permanent archiving for electronic scholarly journals, as well as via the LOCKSS initiative. It operates a fully open access publishing model which allows open global access to its published content. This model is supported through Article Processing Charges. For more information on Article Processing charges in general, click here.PPAR Research is included in many leading abstracting and indexing databases. For a complete list, click here.PPAR Research was founded in 2005 by Professor Mostafa Zaki Badr who served as the Editor-in-Chief of the journal between 2005 and 2011.The most recent Impact Factor for PPAR Research is 2.811 according to the 2016 Journal Citation Reports released by Clarivate Analytics in 2017.
SCI熱門推薦期刊 >
SCI常見問題 >
職稱論文常見問題 >
EI常見問題 >